WO2005025623A3 - Ef-24-factor vii conjugates - Google Patents

Ef-24-factor vii conjugates Download PDF

Info

Publication number
WO2005025623A3
WO2005025623A3 PCT/US2004/024490 US2004024490W WO2005025623A3 WO 2005025623 A3 WO2005025623 A3 WO 2005025623A3 US 2004024490 W US2004024490 W US 2004024490W WO 2005025623 A3 WO2005025623 A3 WO 2005025623A3
Authority
WO
WIPO (PCT)
Prior art keywords
cytotoxic
methods
compositions
protein
delivering
Prior art date
Application number
PCT/US2004/024490
Other languages
French (fr)
Other versions
WO2005025623A2 (en
Inventor
Mamoru Shoji
James P Snyder
Dennis C Liotta
Aiming Sun
Original Assignee
Univ Emory
Mamoru Shoji
James P Snyder
Dennis C Liotta
Aiming Sun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory, Mamoru Shoji, James P Snyder, Dennis C Liotta, Aiming Sun filed Critical Univ Emory
Publication of WO2005025623A2 publication Critical patent/WO2005025623A2/en
Publication of WO2005025623A3 publication Critical patent/WO2005025623A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compositions and methods are provided for delivering cytotoxic compounds, such as natural curcumoids and synthetic curcumin analogs, specifically to cancer cells and to blood vessels that nourish solid tumors. The compositions include a cytotoxic drug tethered to a protein, such as factor VIIa, which can bind with high affinity to a receptor, such as tissue factor, expressed on the surface of cancer cells and vascular endothelial cells within the tumor microenvironment. Upon binding, the drug-protein-receptor complex is endocytosed and the drug is subsequently liberated inside the target cell via proteolytic cleavage. The compositions and methods may increase the efficacy of the cytotoxic agets and decrease their side effects by delivering the agents to specific target cells, such as cancer cells, vascular endothelial cells in a tumor, and metastatic foci anywhere in the body, providing the target cells express surface bound tissue factor. Additionally, methods of synthesis of cytotoxic compound-protein conjugates are provided, for example, curcuminoid-tether-linker-factor VIIa composition, as well as pharmaceutically acceptable compositions and methods for delivering a therapeutically-effective amount of a cytotoxic compound-protein conjugate together with one or more pharmaceutically acceptable carriers (additives) and/or diluents to an animal or human patient.
PCT/US2004/024490 2003-07-28 2004-07-28 Ef-24-factor vii conjugates WO2005025623A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49065603P 2003-07-28 2003-07-28
US60/490,656 2003-07-28

Publications (2)

Publication Number Publication Date
WO2005025623A2 WO2005025623A2 (en) 2005-03-24
WO2005025623A3 true WO2005025623A3 (en) 2005-12-22

Family

ID=34312158

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/024490 WO2005025623A2 (en) 2003-07-28 2004-07-28 Ef-24-factor vii conjugates

Country Status (1)

Country Link
WO (1) WO2005025623A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007098504A1 (en) * 2006-02-24 2007-08-30 Emory University Prodrugs of curcumin analogs
CN100425228C (en) * 2006-08-04 2008-10-15 徐文凯 Dispersion tablets and its prepn. method
UA109633C2 (en) 2008-12-09 2015-09-25 HUMAN ANTIBODY AGAINST TISSUE FACTOR
EP3281956A3 (en) 2010-06-15 2018-04-18 Genmab A/S Human antibody drug conjugates against tissue factor
WO2014022660A1 (en) * 2012-08-03 2014-02-06 Georgia State University Research Foundation, Inc. Curcumin analogs and methods of making and using thereof
WO2015175573A1 (en) * 2014-05-12 2015-11-19 Haus Bioceuticals, Inc. Curcumin-peptide conjugates and formulations thereof
CN106938051B (en) * 2016-08-22 2019-10-11 复旦大学 Target the antibody-drug conjugates of tissue factor
EP3762368B1 (en) 2018-03-08 2022-01-26 Incyte Corporation Aminopyrazine diol compounds as pi3k-y inhibitors
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000201A1 (en) * 1999-06-30 2001-01-04 Emory University Curcumin and curcuminoid inhibition of angiogenesis
WO2001002439A1 (en) * 1999-07-01 2001-01-11 Yale University Neovascular-targeted immunoconjugates
WO2001040188A1 (en) * 1999-12-03 2001-06-07 Emory University Curcumin analogues for treating cancer
WO2001058935A2 (en) * 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
US20020168357A1 (en) * 1997-03-10 2002-11-14 Hing C. Wong Antibodies for inhibiting blood coagulation and methods of use thereof
WO2003075847A2 (en) * 2002-03-08 2003-09-18 Emory University NOVEL CURCUMINOID-FACTOR VIIa CONSTRUCTS AS SUPPRESSORS OF TUMOR GROWTH AND ANGIOGENESIS
WO2004007557A2 (en) * 2002-07-12 2004-01-22 Novo Nordisk A/S Tf antagonist

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020168357A1 (en) * 1997-03-10 2002-11-14 Hing C. Wong Antibodies for inhibiting blood coagulation and methods of use thereof
WO2001000201A1 (en) * 1999-06-30 2001-01-04 Emory University Curcumin and curcuminoid inhibition of angiogenesis
WO2001002439A1 (en) * 1999-07-01 2001-01-11 Yale University Neovascular-targeted immunoconjugates
WO2001040188A1 (en) * 1999-12-03 2001-06-07 Emory University Curcumin analogues for treating cancer
WO2001058935A2 (en) * 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
WO2003075847A2 (en) * 2002-03-08 2003-09-18 Emory University NOVEL CURCUMINOID-FACTOR VIIa CONSTRUCTS AS SUPPRESSORS OF TUMOR GROWTH AND ANGIOGENESIS
US20040009914A1 (en) * 2002-03-08 2004-01-15 Mamoru Shoji Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis
WO2004007557A2 (en) * 2002-07-12 2004-01-22 Novo Nordisk A/S Tf antagonist

Also Published As

Publication number Publication date
WO2005025623A2 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
Quiles et al. Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy
BRPI0416028B8 (en) compound, compound conjugates, pharmaceutical composition and conjugate uses
CA2910494C (en) Insulin-oligomer conjugates, formulations and uses thereof
WO2006113623A3 (en) Elimination of heterogeneous or mixed cell population in tumors
WO2004073656A3 (en) Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
WO2004013093A3 (en) Cytotoxic agents containing novel potent taxanes and their therapeutic use
CA2399866A1 (en) Compositions and methods for treatment of angiogenesis in pathological lesions
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
WO2002060955A3 (en) Modified antibodies and methods of use
WO2006062779A3 (en) Anti-integrin immunoconjugates, methods and uses
EP0954340A4 (en) Targeted combination immunotherapy of cancer
MXPA01011000A (en) Conformationally restricted polyamine analogs as disease therapies.
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
WO2005025623A3 (en) Ef-24-factor vii conjugates
WO2005051315A3 (en) On-demand cleavable linkers for radioconjugates for cancer imaging and therapy
US9636419B2 (en) Targeting multiple receptors on a cell surface for specific cell targeting
EP3102242A2 (en) Targeted drug conjugates
WO2004096159A3 (en) Saposin c-dops: a novel anti-tumor agent
Yu et al. A ferroptosis-inducing and leukemic cell-targeting drug nanocarrier formed by redox-responsive cysteine polymer for acute myeloid leukemia therapy
WO2005065361A3 (en) Compounds and compositions for treating dysproliferative diseases, and methods of use thereof
Gaál et al. Low toxicity and high antitumour activity of daunomycin by conjugation to an immunopotential amphoteric branched polypeptide
TWI807320B (en) Drug conjugates containing alpha-enolase antibodies and uses thereof
RU2326691C2 (en) Urease application for malignant cells inhibition
WO2003075847A3 (en) NOVEL CURCUMINOID-FACTOR VIIa CONSTRUCTS AS SUPPRESSORS OF TUMOR GROWTH AND ANGIOGENESIS
WO2002053700A3 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase